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ABSTRACT
Objective: The objective of the study was to present an overview of regulatory requirements for wound and burn care dressings.
Methods: A total of 80 research and review articles including regulatory guidelines to control the marketing of wound and burn care dressings 
recommended by international regulatory agencies were reviewed.
Results: A wide range of dressings, as a new target of the healing process, have been developed due to continued growth and innovations in the field. 
Ideal dressings should be safe and achieve healing at a reasonable cost with minimum inconvenience to patients. It is mandatory that manufacture 
and sale of such dressings are approved by the relevant health authority of each country. This article provides manufacturers with an overview 
regarding regulatory approval procedures for marketing such dressings in different countries and addresses the gaps and challenges in the existing 
guidelines aimed at maintaining product quality. It provides a comparative analysis of the differences in regulatory requirements and highlights 
that ongoing discussions and appropriate actions are required to support the continuous development of these dressings. Most countries have their 
own regulatory guidelines, and the approval processes differ according to the country. Quality parameters concerning the type of material, pore 
size, sterilization methods, shape and size, and labeling are not discussed in guidelines; therefore, innovators and manufacturers are facing tough 
challenges to showcase their products in the market, and this further leads to either lack of market availability or high cost of such dressings.
Conclusion: Development of common quality guidelines is essential for market availability of low-cost, high-quality dressings.
Key words: Surgical dressings, Wound dressings, Regulated market, Semi-regulated markets, Approval process, Burn dressings.
INTRODUCTION
Burn and wound injury is a prevalent and burdensome critical care 
issue. Furthermore, burn wounds are complex and present unique 
challenges that require specialized care to protect from microbial 
infection [1]. According to the World Health Organization (WHO), more 
than 300,000 deaths occur each year as a consequence of fire-induced 
burns [2]. Approximately 3.5 million burn patients globally enter the 
outpatient health service system and receive some level of medical 
attention. The burden of such injuries generally falls on poor patients as 
they cannot afford costly treatments, and a primary contributing factor 
that leads to infection and finally to death in this population is poor 
hygiene. Burn injury management is challenging, due to significant fluid 
loss, tissue damage, and deep wounds, thus contributing to death [2,3]. 
At present, various novel dressings are being developed worldwide; 
however, due to lack of clear understanding of approval procedures, 
they are not accessible to patients.
This study provides details regarding the regulatory status, including 
approval procedures, and regulatory hurdles for new innovations 
that are not yet available for patient use. Decisions that are made 
regarding regulatory approval for a specific product lie within the 
regulatory authority of the country in which the product is to be 
marketed. A comparative study detailing regulatory requirements, 
approval timelines, and required approval fees in different countries 
has been conducted [2,3]. It has been identified that there is an utmost 
requirement for common regulatory guidelines; especially quality 
guidelines that may help attract more innovators and manufacturers to 
produce such dressings.
Globally, over 100 million surgical incisions occurring per year require 
wound management, indicating a 3.1% compound annual growth 
rate (CAGR) [4]. The prevalence of various wound types is shown in 
Table 1 [4].
A wound is generally defined as a disruption in the continuity of the 
epithelial lining of the skin or mucosa [5]. There are many types of 
wounds with multiple causes for their occurrence. The healing process 
is very complex; to prevent from microbial infection and to facilitate the 
body’s natural healing mechanisms, an optimal healing environment 
and an appropriate wound dressing are often required [6].
There is a wide range of advanced and traditional wound care and burn 
dressings available, and the global wound dressing market is expected 
to expand at a CAGR of 4.5% during the forecast period from 2014 to 
2020. In 2013, the global wound dressing market was estimated to be 
greater than US$7.5 billion, and by 2020 it is projected to be more than 
US$10.1 billion [7]. Standard wound dressings include wound closure 
products (gauze tapes, sponges, surgical cotton swabs, and others), 
basic wound care products, and antiseptic dressings. More advanced 
wound dressings include emerging and existing products such as 
films, foam dressings, Hydrofiber dressings, hydrocolloids, hydrogels, 
collagen dressings, and alginates [8,9]. Various types of advanced 
wound care dressings currently available are shown in Table 2, and 
research and development are ongoing.
Simple wound care or surgical dressings currently available cannot be 
used to cover the entire burned skin surface area of patients. Therefore, 
to overcome the challenges associated with the management of wound 
care and burn injuries, clinical trials are underway to evaluate novel 
products, such as Beta foam and Allevyn Silver dressing for burn 
wounds and acute burns, Inerpan for the treatment of partial-thickness 
burns, and honey for wound management [22,23].
© 2018 The Authors. Published by Innovare Academic Sciences Pvt Ltd. This is an open access article under the CC BY license (http://creativecommons. 
org/licenses/by/4. 0/) DOI: http://dx.doi.org/10.22159/ajpcr.2018.v11i7.26772
Research Article
In general, wound care and burn dressings are classified on the basis 
of the risk associated with the wound and are categorized as medical 
devices [24]. They are classified as Class I–IV and, in some countries, 
they are classified as Class A–D. Class A or Class I wound dressings 
are generally associated with low-risk wounds, and a low regulatory 
standard is required for their approval [24]. General classification is 
shown in Table 3.
In regulated markets (the USA, the European Union [EU], and Japan), 
wound dressings are classified as ClassA medical devices, for which 
no separate dossier submission is required, and maintenance of 
the safety and quality of the product is mainly the manufacturer’s 
responsibility [25]. In emerging markets, they are classified as 
medical devices, although in some countries, proper classification and 
guidelines have not been established yet. These countries seek for 
Table 1: Estimated prevalence and growth rate of various wound 
types, 2011–2020 [4]









Burn wounds 10221 1.2
Chronic wounds 40400 7.6
Carcinoma 618 3.0
Melanoma 103 3.2
Skin cancer 103 3.1
CAGR: Compound annual growth rate
Table 2: Types of advanced wound care and burn dressings
Type of dressing Examples/product brand 
names
Components Intended use References
Advanced wound dressings 
Foam dressings Biatain, tegaderm, restore, 




For use beneath compression 
stockings, for patients with 
venous leg ulcers
[9-11]
Hydrocolloid dressings Biopad, tegasorb, comfeel, 
hydrocoll, varihesive E, 
medihoney tube (Coloplast/
Sween)
Adhesive, absorbent, and 
elastomeric components, 
carboxymethyl cellulose
Intended for use on 
light-to-moderate exuding, 
acute or chronic partial- or 
full-thickness wounds
[9-11]
Film dressings 3M Tegaderm, Pro-claude, 
Polyskin II, ProCyte 
film (proCyte)
Single thin transparent 
sheet of polyurethane 
coated on one side with 
an adhesive
Superficial wounds with little 
exudate, secondary dressing 
to attach a primary absorbent 
dressing
[9-11]
Hydrogel Aquasite, ReliaMed, Anasept, 
Flex derm, Nu-Gel (Dow Hickam, 
Johnson &Johnson)
Three-dimensional 
networks of cross-linked 
hydrophilic polymers
Used to retain the gel in shallow 
wounds
[9-11]
Alginate dressings Bioguard Roll gauze, 
Kerlix AMD, Algicel, 
Melgisorb (Kendall)
Calcium or 
calcium-sodium salts of 
natural polysaccharides
For moist, moderate-to-heavy 
exuding wounds
[9,10,12]
Collagen Prisma, Promogran, 
Stimulen (Systagenix)





Conventional NPWT VAC therapy, vista 
versatile (Boehringer wound 
systems LLC), Engenex®
Consist of three 
components: Porous 
non adhesive packing 
material, occlusive seal, 
airtight container system
Potential to accelerate healing 
process 
[9-13,15,16]
Oxygen and hyperbaric 
oxygen equipment
OxyHeal (OxyHeal Health 
Group)
Hydrogel sheet 
containing glucose and 
an enzyme oxidase 
Stimulates wound healing [9,12,14]
Electrical stimulation 
devices
POSIFECT (Biofisica LLC) Derived from two 3-V 
nominal lithium coin cell 
batteries that deliver 
electric current to the 
wound bed
Stimulates the wound healing 
process
[9,14,17-19]
Active wound care device
Artificial skin and skin 
substitutes




Provides protection from bacterial 
influx and mechanical coverage
[12-14]
Surgical wound care 
Fibrin-based sealants Fibrin-coated wound 
dressing (3M)
A fibrin-coated dressing 
with a flexible film layer, 
a pressure-sensitive 
adhesive layer, and a 
fibrin powder layer 
Used as a scaffold in tissue 
regeneration strategies
[9,16-18]
Collagen-based sealants Regranex, Autogel, Multidex 
gel (Smith and Nephew)
Comprised collagen or 
hyaluronic acid 
Stimulates wound healing [9,12,14]
Anti-infective dressings Silver dressing, Algidex, Aquacel 
Ag (DeRoyal)
Hybrid dressings that 
provide healing advantage
Broad-spectrum activity [9,12,19-21]
NPWT: Negative pressure wound therapy, VAC: Vacuum-assisted closure
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US and EU approval marks and do not ask for additional approval, if 
products have been previously approved in these countries [26-28].
USA
In the USA, surgical and wound care dressings are regulated by the Food 
and Drug Administration (USFDA) under the Medical Device Regulation 
Act and are classified as Class I and II [29]. In general, classification 
depends on the complexity and invasiveness of the dressings. Examples 
of dressings are detailed in Table 4.
For Class I dressings, separate regulatory approval is not required, unlike 
Class II dressings that require 510 (k) approval. This approval process 
requires demonstration of “substantial equivalence” to a similar device 
marketed before 1976 and does not require any clinical research, for 
example, Oasis Wound Matrix, Prisma, and Medihoney [30,31].
Class III wound care dressings are considered to have the highest risk, 
for example, derma graft, designed to restore the dermal bed in diabetic 
foot ulcers, thereby improving the wound healing process and allowing 
patients’ own epithelial cells to migrate to the wound and close it. 
Apligraf is a living cell-based product for chronic venous leg ulcers 
and diabetic foot ulcers. Apligraf is supplied as a living, bi-layered skin 
substitute. These are the only two wound care products approved by 
the FDA under Class III [32].
The well-defined approval procedure for wound care dressings in the 
US motivates researchers to present new and innovative products 
designed for clinical access and application.
Approval procedure
•	 Step	1	(identification	of	classification):	According	to	USFDA	medical	
device guidelines, surgical dressings are categorized as Class II 
medical devices.
•	 Step	2	 (identification	of	predicate):	Before	 registration,	 a	 check	
of predicate devices in the USFDA-provided database is required. 
Predicate devices are listed as similar medical devices prior 




According to the USFDA guidelines, wound care dressings are 
categorized as Class II, for which no separate dossier submission 
is	required.	The	product	classification	codes	are	used	to	determine	
whether any standards and/or guidance documents apply to the 
device. Before submitting the application, applicants are required 






•	 Step4	 (Submission	 request	 to	 FDA):	 Following	 classification	
identification	and	before	final	submission,	a	request	is	made	to	the	
USFDA.
•	 Step	5	 (FDA	 feedback):	The	FDA	will	 review	 the	classification	of	
products and the similarity of claimed predicate devices.
•	 Step	 6	 (submission	 and	 review):	 Applicants	 then	 submit	 the	
application to the FDA and pay for the stated fee to have the 
submission reviewed. FDA will review the submission within 90 days 
and may request additional information, as appropriate. Successful 
applicants will be issued with a 510 (k)-clearance letter, along with 
a 510(k) number by FDA.
•	 Step	7	(issuance	of	a	clearance	letter):	A	clearance	letter	is	required	
to market the product in the USA. A clearance letter is an FDA 
declaration that a product is substantially equivalent to a predicate 
device selected through the 510 (k) process, which has previously 
been cleared by FDA for sale. The clearance letter should be uploaded 
onto the FDA website under “device listing and establishment 
registration	 system”	using	 the	FDA’s	unified	 registration	 listing	
system.
•	 Step	8	(renewal	and	validity):	Once	FDA	issues	a	510	(k)	approval,	a	
number is assigned with an unlimited period of validity. However, it 
is mandatory to remain in compliance with the quality system and 
within all FDA regulations to continue the sale of the product in the 
USA. FDA may conduct random inspections of the manufacturing 
facility to ensure compliance with the quality systems regulation (21 
code for federal regulations part 820.70). The full approval procedure 
is outlined in Fig. 1 [31].
EU
The European Medicines Agency is the regulatory body for wound care 
and burn dressings within the Medical Devices Directive (MDD) 93/42/
EEC [29]. To commercialize wound care and burn dressings in the EU, a 
European Conformity (CE) Mark certificate is needed [33].
Approval procedure
•	 Step	1	(classification	and	applicable	MDD	directive)
 In accordance with the EU Directive93/42/EEC, wound dressings 
are categorized as Class I (non-sterile and non-measuring), or Class I 
(sterile and measuring).
•	 Step	2	(identification	of	regulatory	requirements)
 Before submitting the application, compliance with the following 







 Detailed information concerning the product is provided in this 
section, in accordance with the 94/42/EEC directive. Implementation 
of a QMS is required in accordance with Annexure-II of the Medical 
Device Directive and ISO 13485 standards. Manufacturers are 
Table 3: General classification of wound dressings [24]
Class Risk level Type of dressings 
A Low Wound dressing
B Low-moderate Hydrogel dressings 
C Moderate-high Deep wound dressing
D High Medicated dressings, sterile dressings, 
products containing biomaterials of 
human origin
Table 4: List of dressings and associated level of risk [30]
Type Examples Level of risk FDA classification Regulatory requirements
Fabric dressings Hydrophilic wound dressings, 
occlusive wound dressings, 
hydrogel wound dressings
Low risk Class I Approval not required; the FDA only needs 
to be informed before marketing. It is 
the responsibility of the manufacturer to 








Class II 510 (k) approval is required
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required to submit a declaration of conformity, which is a legally 






 The QMS/technical dossier is reviewed by the regulatory body, and 
an audit is scheduled.
•	 Step	6	(audit	by	the	notified	body)




for the facility are issued.
•	 Step	7	(certification/validity	and	renewal)
	 CE	marking	certificates	are	 typically	valid	 for	3	years.	 ISO	13485	
certification	must	be	renewed	every	year.	Every	year,	the	EU	notified	
body will check compliance with 92/43/EEC. The full approval 
procedure is outlined in Fig. 2 [33-38].
Japan
The MOH, Labor, and Welfare (MHLW) in Japan regulates wound 
care dressings under the medical devices category [29,39]. The 
Japanese Pharmaceutical Affairs Law (PAL) defines wound care 
dressings as medical devices that are intended for use in the 
diagnosis, treatment, or prevention of disease in humans or animals, 
or intended to affect the structure or functions of the bodies of 
humans or animals. To engage in marketing, wound care and burn 
dressings manufacturers should obtain marketing business licenses 
(Marketing Authorization Holder [MAH]). The approval process 
is overseen by the Pharmaceuticals and Medical Devices Agency 
(PMDA), a division of the MHLW. To market surgical or wound 
dressings in Japan, manufacturers/marketing holders must register 
the device through the following procedures:
•	 Step	1	(classification	determination):	According	to	the	Japanese	PAL	
and the Japanese Medical Device Nomenclature codes, wound care 
dressings and surgical dressings are categorized as Class I and as 
general medicine Class I medical devices.
•	 Step	2	(identification	of	regulatory	requirements):	Before	submitting	
an application for marketing approval, manufacturers should prepare 
Fig. 1: Decision tree for the approval process in the United States [29-32]. *Application fees ($5018) are revised annually. Updated information 
concerning fees can be obtained at: Support@fdaagents.com. PMA: Pre-market approval application, FDA: Food and Drug Administration
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the following documents and product information. All documents 
must be written in Japanese.










Color photo, size and weight, components and accessories, electrical 
rating, and block diagram.
•	 Raw	materials:	 Quantity	 (weight	 and	 percentage),	materials	
specification	(chemical	and/or	physical	characteristics).
•	 Product	 specifications	 (defined	according	 to	 each	product),	 for	





and usage of components of other medical devices
•	 Package	inserts	(directions	for	use)	draft
•	 Color	photo	(digital	image).
•	 Step	 3	 (submit	 pre-market	 application):	 Submission	 of	 the	
application for foreign manufacturer accreditation (Form No. 18) 
and implementation of the QMS.
•	 Step	4	(conformity	assessment):	After	submission	of	all	documents	
and required information, a conformity assessment is undertaken 
by the regulatory body.
•	 Step	5	 (certification	or	 renewal	 and	validity):	After	1	month,	 a	
decision regarding approval/rejection is reached by the PMDA. No 
separate	certificate	is	issued	for	Class	I	devices,	and	approval	is	valid	
until there is any change in the QMS. The full approval procedure is 
outlined in Fig. 3 [39].
Canada
Wound care and surgical dressings are classified as medical devices 
and are defined in the Food and drugs act, which “covers a wide range 
of health or medical instruments used in the treatment, mitigation, 
diagnosis, or prevention of a disease or abnormal physical condition.” 
The approval process is regulated by the medical devices regulations 
(MDR) and wound care dressing classifications depend on their 
intended use or the risk associated with the use of dressings. If a product 
is classified as a Class I device, a medical device license is not required. 
The rules governing the classification of medical devices are outlined 
in schedule 1 (parts 1 and 2) of the MDR. The approval procedure is 
detailed in Fig. 4 [40,41].
•	 Step	1	(determining	classification):	In	accordance	with	the	Canadian	
MDR schedule 1, wound care and surgical dressings are categorized 
as Class I medical devices.
•	 Step	2	(identification	of	regulatory	requirements):	Before	application	




Fig. 2: Decision tree for the European Union approval procedure. *Fees vary in 30 member states. More details available on: http://www.
mhra.com/cost-and-fees-for-the-registration-with-MHRA.html **No separate regulatory approval required. Manufacturers can use the CE 
mark if their product fully complies with the EU directive. QMS: Quality management system, MDD; Medical device directive
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•	 ISO	13485:2003	quality	system	management
•	 Safety	and	effectiveness	data.
•	 Step	3	(submission	of	MDEL):	Application	 for	an	MDEL,	 that	 is,	a	
permit for the distributor/importer, or a manufacturer of Class I 
devices. Submission of the MDEL application for Class I devices.
•	 Step	4	 (fee	 submission):	After	 submitting	an	MDEL	application,	
payment of CAD$7344 should be submitted within 30 days to the 
appropriate authority.
•	 Step	5	 (review	of	MDEL	application):	The	MDEL	application	 is	
reviewed by the Canadian Registrar, and the approved application 
is posted on the Health Canada website.
•	 Step	6	 (renewal	 and	validity):	 Following	 approval,	 no	 separate	
certificate	is	issued,	and	under	section	48	of	the	regulations,	license	
holders are required to notify the health authority within 15 days 
in case of a change in the name or address of the license holder, or a 
change in the name, title, or telephone number of the contact person 
identified	on	the	application.
Renewal is not required as licenses have an unlimited period of 
validity, but the MAH is required to pay an annual fee to Health Canada, 
and failure to do so may result in the license being revoked. The full 
procedure is outlined in Fig. 4 [40-42].
Australia
In Australia, surgical and wound care dressings are regulated by the 
Therapeutic Goods Administration (TGA). To obtain access to the 
Australian market, manufacturers are required to register their product 
on the Australian Register of Therapeutic Goods (ARTG). Regulations 
and classification of wound care dressings are similar to those in 
Europe [29,43].
The full approval process, along with the necessary requirements for 
application, is outlined in Fig. 5.
•	 Step	1	(determination	of	classification):	Correct	classification	of	the	
product	is	required	to	register	the	product	in	Australia.	Classification	
can be determined with TGA schedule 2 regarding Australian 
Therapeutic Goods (Medical Devices) Regulations, in which devices 
are categorized as either Class I (non-sterile and non-measuring) or 
Class I (sterile and measuring).
•	 Step	2	(identification	of	regulatory	requirements):	Before	submitting	
the application for approval, applicants should make available the 
documents listed below:
•	 Manufacturer	evidence	of	EU	approval/CE	marking	or	Global	
Medical Device Nomenclature (GMDN) code. If the device has 






Fig. 3: Decision tree for the approval procedure in Japan [38]. 
PMDA; Pharmaceutical and Medical Device Agency, JMDN; 
Japanese Medical Device Number, MAH; Marketing Authorization 
Holder
Fig. 4: Decision tree for the approval procedure in 
Canada*Canadian Medical Device Regulation;**Medical Device 
Establishment License; No fees for Class 1 devices
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•	 Step	3	(application	submission):	The	Australian	sponsor	submits	the	
medical device application online. The application should include an 
intended	purpose	statement,	classification,	and	GMDN	code.
•	 Step	4	 (application	 review):	The	application	 is	 reviewed	by	 the	
Australian regulatory body, and an assessment report is prepared. 
On the basis of the assessment report, a TGA audit of the facility is 
decided.
•	 Step	 5	 (approval/rejection):	 TGA	will	 approve	 or	 reject	 the	
application and, if successful, issue a listing number for the ARTG.
•	 Step	6	(renewal	and	validity):	The	validity	of	the	approval	is	unlimited	
as long as there are no changes to the product or its intended use, 
and the ARTG listing fee of AUD$ 60 is paid annually [43-46].
Brazil
In Brazil, approval is required to market any health, domestic, or 
imported products by the MOH. The National Health Surveillance 
Agency (Agência Nacional de Vigilância Sanitária, ANVISA), a federal 
agency subsidiary to the MOH, is responsible for the regulation, 
control, and supervision of products and services that pose a risk to 
public health. ANVISA issued the Resolution of the Board of directors 
(RDC) No. 185, which regulates the registration of medical devices and 
classifies them into four classes according to the risks associated with 
their use [29,47].
Approval process for surgical dressings
Surgical device manufacturers are required to obtain ANVISA approval 
before selling their products in Brazil. The regulatory requirements for 
approval are similar to those identified in the European MDD 93/42/
EEC 65.
•	 Step	1	(determining	classification)
 According to Annexure II of the Brazilian Resolution RDC 185/2001, 
surgical and wound care dressings are categorized as Class 1 medical 
devices (low risk). There are two registration routes: Cadastro 
and Registro, and it is important to determine whether the device 
requires the Cadastro or the Registro approval process. The Cadastro 
process pertains to lower risk devices. As such, wound care dressings 
require approval through the Cadastro approval process. This review 
process has a simpler application pathway and typically requires less 
time than Registro approvals [47-50].
•	 Step	2	(identification	of	regulatory	requirements)
The following are required:






Other possible ways to satisfy the requirements for all devices include 
obtaining a Certificate of Free Sale, or a device registration certificate 
proving home-country approval from MOH, or demonstrating a proof of 
registration in any two other markets with reasons why the device does 
not have home-country approval.
•	 Step	3	(appointment	of	a	Brazilian	registration	holder	[BRH])
 Company that holds a company working allowance permit from 
ANVISA should be appointed, as the BRH.
•	 Step	4	(application	submission):	Provide	a	letter	of	authorization	to	
the BRH, who will submit the registration application and technical 
file	to	ANVISA.
•	 Step	5	(BRH	audit):	Class	I	device	manufacturers	(Cadastro)	must	
comply with BGMP requirements (ANVISA will not conduct an audit).
•	 Step	 6	 (application	 review):	 ANVISA	 reviews	 the	 registration	
application for all classes. If approved, ANVISA will publish the 
registration	number	in	the	Diário	Oficial	da	União.	Registration	is	
valid for 5 years. The full procedure is outlined in Fig. 6 [47-50].
Fig. 5: Decision tree for the approval procedure in Australia. 
*Australian Therapeutic Goods Regulations, ARTG; Australian 
Register for Therapeutic Goods
Fig. 6: Decision tree for the approval procedure in Brazil. 
BGMP: Brazilian good manufacturing practices, BRH: Brazilian 
registration holder, and ANVISA: National Health Surveillance 
Agency, Brazil 522
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China
The China FDA (CFDA) is responsible for the registration of wound care 
and burn dressings. It is mandatory to obtain pre-market approval from 
the State FDA (SFDA). The Center for Medical Device Evaluation (CMDE) 
is responsible for the registration process. The general administration 
of quality supervision, inspection, and quarantine is responsible for 
mandatory safety registration, certification, and inspection of certain 
devices. The procedures for wound care dressing registration are 
governed by two main regulations. Both regulations describe the legal 
requirements for medical device registration in China [29,51].
The SFDA registration process is divided into five steps, and the 
complete application procedure takes 105 working days, excluding the 
time period for testing or conducting clinical trials. The full procedure 
is outlined in Fig. 7.
•	 Step	1	(classification	of	product):	The	Chinese	classification	system	
for medical devices is similar to the European system; however, there 
are differences and applicants are advised to carefully consult the 
classification	list	published	by	SFDA.	With	reference	to	the	published	
SFDA list, surgical and burn dressings are categorized as Class III 
medical devices.
•	 Step2	(identification	of	regulatory	requirements):	Before	application	














to submit an application and issue a letter of application stipulating 
the relationship between the agent and manufacturer.
•	 Step	4	 (dossier	preparation	and	application	 submission):	Once	
medical	 device	 specifications	 have	 been	 completed	 and	 the	
required	documents	have	been	compiled,	as	identified	in	Step	2,	the	
application should be submitted to SFDA for CMDE review.
•	 Step	 5	 (testing	 review	 of	 application):	 After	 submission	 of	
applications to CMDE, sample testing is undertaken in China. As 
stated in the regulations, sample tests must be completed within 
45 working days. When sample tests have been completed, and the 
applicable fees have been paid, the test laboratory will issue a report 
(valid for 6 months) to be submitted as part of the medical device 
registration.
Type testing may be avoided if the imported medical device meets the 
following criteria:
•	 The	medical	device	has	previously	received	market	approval	by	the	
relevant authority in the country of origin
•	 The	manufacturer	holds	a	valid	ISO	9000	(or	equivalent)	certificate
•	 No	significant	differences	exist	between	the	device	for	application	
and device registered in terms of structure, performance, and safety.
•	 Step	6	(evaluation)
 Technical evaluation involves systematic examination that focuses 
on the safety and effectiveness of the medical device. The evaluation 
is performed by internal CMDE reviewers and may involve external 
experts. On completion of the technical evaluation, CDME will issue 
an evaluation report indicating its judgment on the device. The 
evaluation	report	is	submitted	to	SFDA	for	final	approval.	According	
to related regulations, SFDA may send an inspection/auditing 
group to manufacturers abroad to check for their quality assurance 
system based on Chinese National Standards GB/T 19001–ISO9001, 
19002–ISO9002, and any other relevant medical device standards 
and registered product standards. CMDE will review the application 
and decide within 60 days. CFDA will respond within 10 days and 
provide	a	registration	certificate	within	30	days.	A	decision	tree	for	
the approval procedure in China is outlined in Fig. 7 [51].
Singapore
The Health Sciences Authority (HSA) is the regulatory authority 
responsible for the marketing of wound care and burn dressings in 
Singapore. According to the act and regulations, all sterile wound 
care dressings in Singapore must be registered for approval before 
placement in the Singapore market, unless it is stated that registration 
is not required. Product registration is not required for non-sterile 
dressings, although they must conform with the regulations before 
their placement in the Singapore market [52].
The full approval procedure is detailed below, and the flowchart for the 
procedure is shown in Fig. 8.
•	 Step	1	(classification	of	surgical	dressings):
•	 Class	A,	non-sterile	dressings:	Class	A,	non-sterile	dressings	do	not	
require registration with HSA, although they must conform with the 
essential principles of safety and performance of the products before 
entering the Singapore market.
•	 Class	 A,	 sterile	 dressings:	 Class	 A,	 sterile	 dressings	 require	
submission of an application dossier through the Medical Device 
Information and Communication System (MEDICS), and a payment 
of an application fee is immediately required on submission.
•	 Step	2	(identification	of	regulatory	requirements)
Fig. 7: Decision tree for the approval procedure in China. 
*CDME: Center for Medical Device and Evaluation, SFDA: State Food 
and Drug Administration, CFDA: China Federal Device Authority
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General requirements
•	 The	product	must	be	approved	by	the	Global	Harmonization	Task	









origin used, and the manufacturing process, if applicable
•	 Sources	 of	 all	materials	 of	 animal,	 human,	microbial,	 and/or	






A non-sterile dressing is exempt from fees; however, the application fee 
for sterile dressings is $25, and there is no evaluation fee. In general, 
market approval for sterile dressings can be obtained within 30 
working days.
•	 Step	3	 (submission	of	 application):	The	dossier	 is	 submitted	 in	
HSAGN-15 format, electronically through MEDICS.
•	 Step	4	(review	of	application	dossier):	The	review	conducted	by	the	
HSA is based on the supporting data, which have been submitted 
by	 the	 applicants.	 If	 clarification	 or	 additional	 information	 is	
required, HSA will request further information from the applicants. 
A regulatory decision and listing in the Singapore Medical Device 
Register (SMDR) for successful registration, on review of the 
application submitted, is made by HSA. Applications that have 
satisfied	 the	 registration	 requirements	 are	 then	 registered	and	
listed in SMDR. The approval timeline for these types of dressings 
is 1 month.
•	 Step	5	(evaluation	process)	-	full	evaluation	route:	Surgical	dressings	
that have not been approved by any of the H as reference agencies 
will be subjected to the full evaluation route.
Abridged evaluation route
Surgical dressings that have been previously registered with at least 
one HSA reference regulatory agency for a labeled use identical to 
that intended for marketing in Singapore are eligible for the abridged 
evaluation route. A decision tree highlighting the approval procedure in 
Singapore is provided in Fig. 8 [52-61].
Malaysia
The Malaysian medical device regulatory framework is based on 
the global harmonization trend, as promoted by GHTF, the Asian 
Harmonization Working Party and Medical Device Product Working 
Group of the Association of Southeast Asian Nations Consultative 
Committee for Standards and Quality, and supported by the WHO [29].
The Malaysian Medical Device Authority (MDA) is responsible for 
enforcing medical device regulations and medical device registration. 
The full approval procedure is outlined and highlighted in Fig. 9.
•	 Step	1	(classification):	According	to	the	Malaysian	Medical	Device	
Regulations, surgical and wound care dressings are categorized as 
Class A devices. Class A is further subdivided into Class A non-active 
and Class A active sterile groups.
•	 Class	A,	non-active	sterile	dressings:	Class	A	non-sterile	devices	
do not require registration, but approval in the reference country 
is required. To market Class A non-sterile surgical dressings, it 
is mandatory to notify the MDA.
•	 Class	A,	active	sterile	dressings:	Submission	of	an	application	
dossier using the Common Submission Dossier Template (CSDT) 
format is required.
•	 Step	2	 (identification	of	 regulatory	 requirements):	The	medical	











and wound dressings in Malaysia, an authorized representative in 
Malaysia must be appointed.
•	 Step	4	 (preparation	and	submission	of	dossier):	The	authorized	
representative prepares the registration application dossier and 
submits the application to the Malaysian MDA online.
•	 Step	 5	 (review	 of	 the	 dossier):	 An	 independent	 conformity	
assessment body (CAB) reviews the registration application dossier 
and	issues	a	CAB	certificate	that	is	then	submitted	to	the	MDA.	Fig. 9 
details a decision tree for the approval procedure in Malaysia [62-66].
Fig. 8: Decision tree for the approval procedure in Singapore. 
*Health Science Authority, ** Medical Device Information and 
Communication System, ***Singapore Medical Device Register, 
and CAB: Confirmatory Assessment Board
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Mexico
In Mexico, wound care and burn dressings are classified on the basis of 
the risk associated with their use. They are classified as medical devices 
and are regulated by the Federal Commission for Protection of Sanitary 
Risks (Comisión Federal para la Protección contra Riesgos Sanitarios, or 
“COFEPRIS”), which is a division of the Secretariat of Health (Secretaría 
de Salud).
Foreign manufacturers are not permitted to submit registration 
applications directly to COFEPRIS and instead must appoint a Mexican 
distributor or local Mexican registration holder (MRH) to act on their 
behalf. The full approval procedure is described below and a detailed 
flowchart is provided in Fig. 10.
•	 Step	1	(classification	determination)
	 The	first	step	for	registration	in	Mexico	is	to	determine	the	class	
of the device. Wound care and burn dressings are categorized 
as Class I, that is, low-risk medical devices. Products within this 
category have been previously well-established, with a long-
standing history of registration, approval, and proven safety and 
effectiveness, and are generally not introduced into the body. 
These products must be registered; however, technical data are 
not required to support registration.
•	 Step	2	(identification	of	regulatory	requirements)
The following list outlines the documents that manufacturers must 












 An MRH must be appointed, who is licensed by COFEPRIS and located 
in Mexico, and who will submit the application to COFEPRIS. The 
appointed MRH will also be responsible for coordinating importation 
of the device; therefore, the MRH must maintain warehouses that 
comply	with	COFEPRIS’	specifications.
•	 Step	4	(COFEPRIS	review)
 A third-party reviewer (TPR) is a private commercial entity 
authorized by COFEPRIS to conduct an initial review of an application 
Fig. 9: Decision tree for the approval procedure in Malaysia. CAB: Confirmatory Assessment Body. *Recognized reference markets include: 
Australia, Canada, EU, Japan, and USA
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Fig. 10: Decision tree for the approval procedure in Mexico Fees is 
set by the authority on the basis of risk assessment, according to 
the federal law on fee payment. MRH: Mexican Residence Holder. 
# SLA: State Licensing Authority, CLA: Central Licensing Authority. 
*Audit of Facility by Notified body is carried out after approval of 
Class A medical device
and,	if	satisfied,	write	a	technical	report	for	COFEPRIS	recommending	
approval. While an additional cost is incurred for a TPR, typically no 
additional information will be required by COFEPRIS after the TPR 
issues their report. In addition, as TPRs are commercial entities, 
they may be more responsive and review applications more quickly, 
resulting in a shorter review process overall. After reviewing the 
report, if there are no further requests for information, COFEPRIS 
will	issue	the	final	registration	certificate	within	30	days.
•	 Step	5	(issuance	of	the	certificate	of	approval)
	 Once	COFEPRIS	approves	an	application	and	 issues	a	 certificate,	
confirmation	 and	 registration	number	 are	posted	 on	 the	MOH	
website. If COFEPRIS has any concerns with the registration, it will 
inform manufacturers in writing. On such occasions, the time limit 
for approval is lifted and longer time may be required to approve a 
registration. A decision tree for the approval procedure in Mexico is 




Wound care and burn dressings in India are currently included in 
the new Medical Devices Rules 2017, under subsection (1) of section 
12 and subsection (1) of section 3 of the Drugs and Cosmetics Act, 
1940 [69].
Burn dressings are not classified separately in the Medical Devices 
Act, however, according to the medical device classification detailed in 
Schedule I, Part I, they are classified on the basis of their intended use.
•	 Step	1	(identification	of	classification)
 Wound care and burn dressings are categorized as Class A-D medical 
device as in contact with injured skin. In addition, subject to clause 
(c), a non-invasive medical device in contact with injured skin shall 
be assigned a Class B categorization, as it is principally intended for 
the management of the microenvironment of a wound.
•	 Step	2	(identification	of	regulatory	requirements)
 The domestic manufacturer or authorized agent shall submit a 
signed form along with the following information pertaining to the 
manufacturing site as provided in Table 5.
•	 Step	3	(submission	of	application)
 The State Drugs Controller serves as the State Licensing Authority 
(SLA) and shall be the competent authority for enforcement of the 
rules relating to the manufacture of Class A or Class B medical devices 
and the sale, stocking, and exhibition of medical devices, and other 
related functions. Class C and D high-risk devices are regulated by 
the Central Licensing Authority (CLA), which oversees the clinical 
investigation and clinical performance evaluation of medical devices 
and has other related functions. If the manufacturer intends to 
manufacture a predicate medical device, the manufacturer must 
receive approval from CLA before applying to the SLA.
•	 Step	4	(issuing	the	license)
 The manufacturing site of the applicant, in respect to a Class B device, 
shall	conform	with	the	QMS	requirements,	as	specified	in	the	fifth	




 A license issued using the MD-5 form shall remain valid in perpetuity, 
subject	 to	payment	of	a	 license	 retention	 fee,	 as	 specified	 in	 the	
second schedule before completion of the period of 5 years from 
the date of its issue; unless it is suspended or canceled by SLA or 
CLA [68]. A decision tree for the approval procedure in India is 
provided in Fig. 11.
Israel
Israel is one of the world’s leading centers for the development of 
innovative medical devices [71]. In Israel, wound care dressings are 
categorized as medical devices. All regulations related to medical 
devices are also applicable to wound care and burn dressings. Wound 
care dressings manufactured or marketed in Israel must be registered 
with the MOH Registrar (AMAR - the Medical Device Division of the 
Israeli MOH) [72].
Registration of wound care dressings in Israel is based on prior approval 
in one of the following countries: Australia, Canada, EU, Iceland, Norway, 
New Zealand, Switzerland, Japan, or USA.
The registration procedure for wound care dressings is described and 
the process flow is shown in Fig. 12.
•	 Step	1	(identification	of	classification)
 Wound care dressings are categorized as medical devices, and all 
regulations regarding medical devices are applicable.
•	 Step	2	(identification	of	regulatory	requirements)
 Manufacturers of wound care dressings should make available the 







 Following determination of the category, a local IRH must be 
appointed, licensed and located in Israel. The appointed IRH will also 
coordinate importation of the device and must maintain warehouses 
that	 comply	with	 Israeli	 specifications.	The	 IRH	will	 submit	 the	
applications to AMAR.
•	 Step	4	(application	submission)
 The IRH will submit the above-listed documents to the AMAR-Medical 
Device Division of the Israeli MOH.
•	 Step	5	(review	of	application)
 AMAR will review the application within 120 days; however, 
registration is usually completed within 6–9 months because 
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Table 5: List of documents required for manufacturer registration and for importation of dressings





Working principle and use of 








Constitution details of domestic 
manufacturer or authorized agent
Site or plant master file
Device master file
Essential principle checklist for 
demonstrating conformity for safety and 
performance
Quality control data
Signed undertaking agreement stating that 











Pilot and pivotal clinical investigation data
Regulatory status and restrictions in use
Proposed instructions for use 
For importation
Notarized copy of overseas manufacturing site or FSC
Notarized copy of QMS
Self-attested wholesale license
Copy of latest inspection report
FSC: Free sale certificate
Fig. 11: Decision tree for the approval procedure in India [69-71] 527
 Vibhuyadav et al.
Asian J Pharm Clin Res, Vol 11, Issue 7, 2018, 516-535
authorities will often require further documentation during the 
course of the evaluation.
•	 Step	6	(issuance	of	certificate	and	validity)
After successful completion of all evaluation steps, AMAR will issue the 
registration certificate, which is valid for 5 years. The license expiration 
date is based on the current regulatory certificate and is subject to the 
device’s CE mark or FDA approval. Fig. 12 details approval procedures 
in Israel.
Russia
In the Russian Federation, all wound care and burn dressings are 
categorized as medical devices. For diagnostic and therapeutic use, 
they must be registered in Moscow, at the Central Department of 
Federal Service on Surveillance in Healthcare and Social Development 
(Roszdravnadzor) [73].
•	 Step	1	(identification	of	classification)
 In accordance with Government Standardization (GOST) R 51609-
2000 medical products, surgical dressings/wound care dressings are 
categorized as Class I (products with a low risk for environmental, 
individual, and public health). Examples are medical devices used 
in hygiene, diagnostics, medication and nursing, single-use linen, 
dressing materials except for special and high-standard dressing 
materials, retentive bandages, and appliances. Applicants should 
















should be appointed. An RRH must be licensed and located in Russia. 
RRHs coordinate importation of the device and must maintain 
warehouses	that	comply	with	Russian	specifications.	The	RRH	will	
submit applications to the Russian MDA.
•	 Step	3	(Dossier	preparation)
 If testing is required, an application for an import license for the 
samples is required, and sample testing is conducted at government-
authorized testing and medical centers within Russia. Preparation of 
the registration dossier should include testing results and medical 
reports.	All	documents	should	be	submitted	to	the	relevant	officials.
•	 Step	4	(application	review)
Review of the application is undertaken within 120 days, and a 
certificate is issued if all test results and submitted documents have 
been approved. Fig. 13 details the decision tree for the approval 
procedure in Russia [73-75].
The comparative study (detailed below in Table 6) shows that some 
countries have heavy fees levied on the MAH for product registration 
and license maintenance that restrict the marketing of innovative 
products despite posing no risks to health.
DISCUSSION
From the details provided above, it is apparent that, for all countries 
mentioned, wound care and burn dressings are categorized under 
medical devices, and therefore, respective regulations are applicable on 
wound care and burn dressings. Despite the similar classification system 
in several countries, differences remain in various documentation 
requirements and dossier content submission, as well as in evaluation 
procedures. Differences, regarding dossier submission format, are 
detailed in Table 7.
The main difference in the content and format of import and export 
licenses for regulated and semi-regulated countries lies in the 
different classification of the same dressing. Some countries share a 
harmonization process; if a device is approved in one country, it may 
then be exported, due to mutual recognition agreements. Australia 
generally requires products with a CE mark. In India, dressings with 
FDA approval or EU mark may be approved and marketed more readily.
The various challenges encountered while drafting quality guidelines 
prevent the development of these guidelines, and also restrict 
manufacturers from maintaining the quality of the products. The 
following gaps/challenges are identified:
Wound size and type
Quantitative measurements of wound sizes are routinely used to 
assess an initial wound pre- and post-debridement. There are no 
standardization/validation guidelines for instruments such as Doppler 
sonography and filament testing used in the assessment of wound 
types [78].
Unavailability of quality testing parameters/guidelines/
monographs
To harmonize the quality of new products, there should be suitable test 
procedures in monographs [78].
Absence of suitable guidelines for clinical trials
The included patient population in clinical trials should be appropriate 
for the type of wounds to be studied. The selected patient population 
Fig. 12: Decision tree for the approval procedure in Israel [71,72]. 
GHTF: Global harmonization task force, AMAR; a department 
within the Israeli MOH responsible for licensing medical devices, 
and IRH: Israeli Residence Holder
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should contribute to the optimization of the study’s capacity to detect a 
treatment effect. There are no available ideal animal models for chronic/
extensive wounds to assess the activity of wound treatment products. 
There are no ideal animal models for chronic wounds to estimate in vivo 
distribution and pharmacokinetic (BD/PK) profiles, which generally 
provide helpful data for the design of toxicology studies including 
carcinogenicity, and reproduction, and genotoxicity studies [78].
Microbial control
There is no specific procedure for the sterilization of different wound 
care products [78].
Missing suitable selection procedures for the use of dressings
Selection of wound care dressings generally depends on the type of 
wound. For burns, the selection procedure should include the burn 
site, extent of burn, type of first aid used, patient ability to manage the 
dressings, cause of the burn, associated pain, urgency of time healing, 
and cost [78].
Miscellaneous challenges
According to Bairy et al. [79], “burns afflict all segments of society, the 
rich, the poor, men and women, and children and old may fall victim 
to it.” Scientists and firms face various challenges in the development 
of new therapies or products for wound care and burn dressings. 
Clearly, this is a complicated and difficult process with many potential 
pitfalls. It is difficult to acquire sufficient funding and navigate the 
Fig. 13: Decision tree for the approval procedure in Russia. 
Roszdravnadzor; Federal service for control over health care and 
social development, RRH: Russian Resident holder. *Conformity 
Assessment: A declaration certifying that the product conforms 
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regulatory environment. Furthermore, when increasing production, 
addressing logistics, and managing the cost of goods, manufacturing 
sites may compromise profitability and risk the long-term viability of 
the enterprise [76-78].
Systems for approving advanced dressings must clearly define pathways 
to market important innovations while also ensuring that patients are 
adequately protected. To achieve these goals, there should be a combination 
of premarket testing and post-market vigilance but with some marked 
contrasts in their approaches. Features of both environments require 
reform, as well as continuous research to assess policy changes.
CONCLUSION
Wounds are inescapable events in life. Wounds may a rise due to physical, 
chemical, or microbial agents [80]. Our study reveals that wound care 
dressings are classified as medical devices and are categorized based 
on the risks associated with their use. Despite categorization as medical 
devices, wound care dressings are not clearly defined in any country. 
Most current challenges include the lack of a proper definition, quality 
standard specifications, requirements for preparation of the dossier, 
drawings and designs, and the quality of materials to be used. It has 
been identified that there is no specific or common dossier format 
available globally for market approval of such dressings. Systematic 
guidelines regarding wound care dressings are likely to help overcome 
delays in regulatory approval and will provide a better understanding 
to manufacturers and innovators about the specific requirements.
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